Ionis Pharmaceuticals posted better-than-expected revenue in the third quarter, but faced challenges as it prepares to bring ...

PD-1 and PD-L1 immune checkpoint inhibitors (ICIs) for treating advanced cancer were associated with an increased risk of new ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

In its latest financial report, Monte Rosa Therapeutics has announced a significant partnership with Novartis, alongside progress in its pipeline of drug candidates. The partnership involves a global ...

The FDA continues to approve new drugs and expand indications for others at a rapid pace. Here’s a summary of what happened ...

Novartis AG's ( VTX:NOVN ) earnings announcement last week was disappointing for investors, despite the decent ...

With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...

Big pharmaceutical companies including the two big Swiss players, Roche and Novartis, had a lot at stake in the US ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

With the seven-year experience of attending the China International Import Expo, Guan Hong, a senior executive at Novartis ...